Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Sobi (Swedish Orphan Biovitrum AB)
Sobi (Swedish Orphan Biovitrum AB)
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Schenck Process FPM becomes Coperion
Effective August 1, 2024, the company will officially transition its name under Coperion, whilst also providing more resources and broader technology capabilities to customers
Torbay Pharma strengthens leadership team to support North American growth strategy
The company has welcomed Mohammed Nazir as Chief Operating Officer (COO) and Tara Slivey as Chief Product Officer (CPO)
Ingenza expands codABLE gene design algorithm to aid recombinant protein production in yeast
The codABLE platform can help to accelerate the development and production of proteins in yeast hosts
DevPro Biopharma and Bespak complete early studies for novel sustainable albuterol inhaler
The novel formulation exhibits a low global warming potential (GWP) and shows comparable performance to Ventolin HFA
Upcoming event
BIO International Convention Digital
3-6 June, 2024 | Convention | San Diego, US
See all
Related Content
Ingredients
Therapeutic: loncastuximab tesirine for diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of blood cancer. Up to 40% of patients will require further lines of treatment as their disease relapses or becomes refractory to first line treatment
Ingredients
Therapeutic for paroxysmal nocturnal haemoglobinuria: pegcetacoplan
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare and chronic blood disorder in which red blood cells are destroyed via extravascular and intravascular haemolysis
Finance
Sobi to acquire Synagis US rights from AstraZeneca
Synagis, the only approved respiratory syncytial virus prophylaxis for high-risk infants, complements Sobi’s expertise in paediatrics and immunology
Recruitment
Fredrik Wetterlundh joins Sobi
Pharmaceutical
Sobi establishes new leadership structure and appoints Torbjorn Hallberg as General Counsel
Pharmaceutical
Norbert Oppitz joins Sobi as new Senior VP, Specialty Care
Finance
Sobi enters into new distribution agreement with Valeant for Ammonul
The company has entered into a three-year agreement with Valeant Pharmaceuticals Ireland for the distribution in Europe, the Middle East and North Africa
Subscribe now